Marc Bellemare with interesting thoughts on the positives and negatives of using RCTs in development economics. I am chewing on what these observations mean for U.S. health policy, and when the sentiment ‘we wish we could do a RCT but we can’t’ is true, and when it is not. Thoughts?
Masthead
Editors in Chief
Austin Frakt
Aaron Carroll
Managing Editor
Adrianna McIntyre
Contributors
Kevin Outterson
Bill Gardner
Nicholas Bagley
Other ContributorsRecent posts
- How Useful Are Temperature Screenings for Covid?
- Veterans Experience Differences Between VHA and Community Providers
- The Health Of The People Should Be The Supreme Law
- What Can Be Learned From Differing Rates of Suicide Among Groups
- At-Home Testing for Covid
- Bias In, Bias Out
- Come work with me (and colleagues you’ve read here)
- Covid Vaccine Facts with the WHO’s Dr. Kate O’Brien
- Nest Protect and the nuclear option
- Religion and COVID: at odds?
Archives
For speaking inquiries
Interested in having Aaron or Austin speak to your group?
For information on Aaron speaking, click here.
For information on Austin speaking, contact the Leigh Bureau.
Aaron’s stuff
Selected appearances:
The Colbert Report
Good Morning America
Sound Medicine (most recent)
The Ed ShowAustin’s stuff
Click here for links to Austin’s peer-reviewed publications and/or related posts.
RCTs in Economics
05/26/2011
Don Taylor
item.php
Follow the blog
TIE Books
Amazon.com
Barnes & Noble
Indiebound
iBooks
Google
Kobo
Amazon.com
Barnes & Noble
Books-A-Million
iBooks
IndieBound
Powells
Buy at Amazon.com
Summary
Excerpt: Economic profit
Excerpt: Diminishing marginal utility
Excerpt: Four factors of production
Excerpt: Monopoly marginal revenue
Excerpt: Consumer/producer surplus
Amazon.com
Barnes & Noble
Books-A-Million
Borders
IndieBound
Powells
Borders
Barnes & Noble
IndieBound
Amazon.com
Books-A-Million
Powells
Austin and Aaron are participants in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to amazon.com.Tag cloud
ACA AcademyHealth access accountable care organizations Affordable Care Act announcement blogging cancer comic competitive bidding costs cost shifting COVID-19 employer-sponsored health insurance health care costs Healthcare Triage health insurance health insurance mandates health reform hospital readmissions hospitals individual mandate insurance exchange market power Massachusetts Medicaid Medicare Medicare Advantage mortality nutrition obesity On The Record physicians politics PPACA premiums prescription drugs quality reading list reflex RWJF spending uninsured Upshot vaccines
by Jess on May 26th, 2011 at 20:49
Ethics is as import for RCTs in development economics as it is for RCTs in medicine. While medical researchers have not always lived up to their own standards in this area, the development profession (my own field) has a particularly poor track record in studying – and changing – the lives of poor people. While the ethics of conducting RCTs in development economics has received considerable attention, as far as I am aware there is no development economics equivalent to the Helsinki Declaration.
To use Bellemare’s example, is it ethical to observe children’s school attendance and performance, but to not to provide deworming medication to the control group? Can equipose truly be assumed? In other words, would YOU rather your child was in the treatment group or the control group?
by Don Taylor on May 26th, 2011 at 22:05
@Jess
Interesting point about different disciplines having different levels of ethics/conventions about conduct of research. Similarly, I think that RCTs in pharmaceuticals are ahead of the game on aggregating/reporting results.
I think that in pharma research, most participants would rather be in treatment group as well, because it holds out hope for a ‘miracle cure’ but it does seem different if control is to observed something (truancy) that we are almost certain is bad.
by Brad F on May 27th, 2011 at 05:56
Don
On the ethics of RCTs and pharma, things are changing. Are they (pharma), playing by the rules? You be the judge:
http://www.vanityfair.com/politics/features/2011/01/deadly-medicine-201101
Brad
by Don Taylor on May 27th, 2011 at 09:23
@Brad F
Interesting article. This makes the point that just having a set of rules and procedures for reporting results doesn’t mean everything is as it should be. The pharma RCTs world is big and has many issues and many involved. Many of my questions go to issues of RCTs for other interventions, like palliative care. Or disease management. You could have the issue of internal validity straight (x causes y), but have no external validity (not replicable). I will try and sketch out some of these thoughts more clearly and post next week.